Precision Medicine for Coronary Artery Disease with Optical Flow Microcatheters

“echoppoint是一家总部位于英国的医疗技术中小企业，在增强诊断方面处于领先地位。他们的第一款产品将解决在心脏病支架植入过程中更好地评估心脏动脉内血流的迫切需求，从而能够精确诊断患者的病情并为患者提供具体的治疗建议。因此，这将改善患者在这种生死攸关的情况下的结果。他们设计了一种微型感应导管，直径不到半毫米，可以由医生通过导管进入心脏，指导血管内胆固醇阻塞的治疗。独特的是，它能够同时感知许多不同的信号，比如千分之一度的血液温度和血管内部的血液流动。将这些高度特异性的测量方法与高保真心电图（ECG）信号相结合，将使微血管生理学的信息达到前所未有的水平，并为未来的广泛发展奠定基础。在精准医疗加速器的支持下，Echopoint将完成导管和控制台的设计，并开发分析工具，以利用高度特定的患者数据，为治疗医生提供明确的治疗建议。一项10例患者首次人体临床研究（FIH）将证明该概念的早期临床证明。因此，该项目将完成迈向全新光纤传感平台商业化的关键步骤。回声点团队由各自领域公认的领导者组成。顶尖的光学、电气和生物医学工程师、心脏病专家和经验丰富的医疗技术业务专家将带领这家高度创新的公司成功实现商业化。精准医疗投资加速器提供了吸引主要私人和风险投资所需的宝贵保证和降低风险。它将使echoppoint作为一个新的英国高科技大学推出，加速其新的传感技术的发展，为NHS和世界各地的患者带来好处。echoppoint开发的平台将影响医疗诊断的许多方面，为医生提供增强的信息，从而确保提供最有效和适用的治疗。”

"Echopoint are a UK-based medical technology SME at the cutting edge of enhanced diagnostics. Their first product will address the urgent need for better assessment of blood flow within heart arteries during stenting procedures for heart attacks, enabling a precise diagnosis of the patient's condition and patient-specific recommendations for treatment. This will thereby improve the patients outcome in this life-or-death situation.They have designed a miniaturised sensing catheter, less than half a millimetre in diameter, that is able to be passed by doctors into the heart to guide treatment of cholesterol blockages within the blood vessels. Uniquely, it is able to sense many different signals at once, such as blood temperature to one thousandth of a degree and the flow of blood within the vessel itself. Combining these highly specific measures with high-fidelity electrocardiogram (ECG) signals will enable an unprecedented level of information about microvascular physiology, and provide a foundation for a wide range of future developments. Supported by the Precision Medicine Accelerator, Echopoint will finalise the catheter and console design, and develop the analytic tools to leverage highly specific patient data to provide clear treatment recommendations to treating physicians. A 10 patient First In Human (FIH) clinical study will demonstrate early clinical proof of concept.The project will thus accomplish key steps towards the commercialisation of an entirely new fibre-optic sensing platform.The Echopoint team are made up of recognised leaders in their fields. Top optical, electrical and biomedical engineers are joined by a cardiologist and an experienced medtech business expert who will lead this highly innovative company through to successful commercialisation. The Precision Medicine Investment Accelerator provides valuable assurance and risk-reduction that is required to attract the major private and venture funding. It will enable Echopoint to launch as a new UK based, high-tech University spin out, acceleration the development of its new sensing technologies to bring benefits for patients in the NHS and worldwide.The platform developed by Echopoint is poised to affect many facets of medical diagnosis by providing enhanced information for doctors and thereby ensuring the most effective and applicable treatment is provided."